- Home
- URG vs SLS Comparison
URG vs SLS Comparison
Compare URG & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | URG | SLS |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.4M | 706.7M |
| IPO Year | 2006 | 2007 |
Fundamental Metrics
Financial Performance| Metric | URG | SLS |
|---|---|---|
| Price | $1.72 | $4.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $2.57 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 7.0M | 5.0M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,207,000.00 | N/A |
| Revenue This Year | $200.42 | N/A |
| Revenue Next Year | $98.46 | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.67 | $1.35 |
| 52 Week High | $2.35 | $6.14 |
Technical Indicators
Market Signals| Indicator | URG | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 60.18 | 47.65 |
| Support Level | $1.47 | $3.35 |
| Resistance Level | $1.74 | $4.84 |
| Average True Range (ATR) | 0.10 | 0.30 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 68.10 | 38.98 |
Price Performance
Historical ComparisonAbout URG Ur Energy Inc (Canada)
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.